A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
AbbVie
AbbVie
Ruijin Hospital
Spanish Lung Cancer Group
Karolinska University Hospital
UNICANCER
Clovis Oncology, Inc.
Shanghai University of Traditional Chinese Medicine
Sanofi
New Mexico Cancer Research Alliance
Hellenic Oncology Research Group
Sanofi
Cell Genesys
Hellenic Oncology Research Group
Cell Genesys